Abstract
Avian influenza A(H5N1) poses a risk to public health due to its pandemic potential should the virus mutate to become human-to-human transmissible. To date, reported influenza A(H5N1) human cases have typically occurred in the lower respiratory tract with a high case fatality rate. There is prior evidence of some influenza A(H5N1) strains being just five amino acid mutations away from achieving droplet transmissibility, possibly allowing them to be spread between humans. Three of these amino acid mutations must occur within a single human host, though the exact probability of such mutations occurring is not currently known. Here, we present a mechanistic within-host infection model for influenza A(H5N1), novel for its explicit consideration of the biological differences between the upper and lower respiratory tracts. These developments enable us to estimate a distribution of viral lifespans and effective replication rates in human H5N1 influenza cases. We combine our within-host model with a viral mutation model to determine the probability of an infected individual generating a droplet transmissible strain of influenza A(H5N1) through mutation. For three required mutations, we found a peak probability of approximately 10−3 that a human case of H5N1 influenza produces at least one virion during the infectious period. Our findings provide insights into the risk of differing infectious pathways of influenza A(H5N1) (namely the avian-human vs the avian-mammal-human routes), demonstrating the three-mutation pathway being a cause of concern in human cases. Additionally, our framework - combining a within-host infection model with a branching process model for viral mutation - is generalisable to other pathogens, allowing mutation probabilities to be more easily ascertained. Our findings are a starting point for further modelling of influenza A(H5N1) and other pathogens where differing tissue susceptibilities and human-to-human transmission is of concern.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
DH, LJ, RS and MJK were supported by the Engineering and Physical Sciences Research Council through the MathSys CDT [grant number EP/S022244/1]. MJK was also supported by the Medical Research Council through the JUNIPER partnership award [grant number MR/X018598/1]. EMH is also linked with the JUNIPER partnership (MRC grant no MR/X018598/1) and would like to acknowledge their help and support. EMH is supported by the NIHR Health Protection Research Unit in Gastrointestinal Infections at the University of Liverpool (PB-PG-NIHR-200910), a partnership with the UK Health Security Agency in collaboration with the University of Warwick. The research was funded by The Pandemic Institute, formed of seven founding partners: The University of Liverpool, Liverpool School of Tropical Medicine, Liverpool John Moores University, Liverpool City Council, Liverpool City Region Combined Authority, Liverpool University Hospital Foundation Trust, and Knowledge Quarter Liverpool. EMH is based at The University of Liverpool. The views expressed are those of the author(s) and not necessarily those of The Pandemic Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used openly available human data, specifically the viral titres of six hospitalised H5N1 influenza patients in Vietnam in 2004 and 2005. These data were originally located in the study by de Jong et al, "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia". (Nature Medicine 12(10):1203-1207 (2006). doi:10.1038/nm1477)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data utilised in this study are publicly available, with relevant references and data repositories provided. The code repository for the study is available at: https://github.com/joshlooks/avianflu.
